|
1
|
Hafizi S and Dahlbäck B: Signalling and
functional diversity within the Axl subfamily of receptor tyrosine
kinases. Cytokine Growth Factor Rev. 17:295–304. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Graham DK, DeRyckere D, Davies KD and Earp
HS: The TAM family: Phosphatidylserine sensing receptor tyrosine
kinases gone awry in cancer. Nat Rev Cancer. 14:769–785. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qu X, Liu J, Zhong X, Li X and Zhang Q:
Role of AXL expression in non-small cell lung cancer. Oncol Lett.
12:5085–5091. 2016.PubMed/NCBI
|
|
5
|
Zhang Z, Lee JC, Lin L, Olivas V, Au V,
LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al:
Activation of the AXL kinase causes resistance to EGFR-targeted
therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilson C, Ye X, Pham T, Lin E, Chan S,
McNamara E, Neve RM, Belmont L, Koeppen H, Yauch RL, et al: AXL
inhibition sensitizes mesenchymal cancer cells to antimitotic
drugs. Cancer Res. 74:5878–5890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Byers LA, Diao L, Wang J, Saintigny P,
Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al: An
epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a
therapeutic target for overcoming EGFR inhibitor resistance. Clin
Cancer Res. 19:279–290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
9
|
Asiedu MK, Beauchamp-Perez FD, Ingle JN,
Behrens MD, Radisky DC and Knutson KL: AXL induces
epithelial-to-mesenchymal transition and regulates the function of
breast cancer stem cells. Oncogene. 33:1316–1324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:pp. 1124–1129. 2010;
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mishra A, Wang J, Shiozawa Y, McGee S, Kim
J, Jung Y, Joseph J, Berry JE, Havens A, Pienta KJ and Taichman RS:
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate
cancer. Mol Cancer Res. 10:703–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antony J, Tan TZ, Kelly Z, Low J, Choolani
M, Recchi C, Gabra H, Thiery JP and Huang RY: The GAS6-AXL
signaling network is a mesenchymal (Mes) molecular subtype-specific
therapeutic target for ovarian cancer. Sci Signal. 9:ra972016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koorstra JB, Karikari CA, Feldmann G,
Bisht S, Rojas PL, Offerhaus GJ, Alvarez H and Maitra A: The Axl
receptor tyrosine kinase confers an adverse prognostic influence in
pancreatic cancer and represents a new therapeutic target. Cancer
Biol Ther. 8:618–626. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kirane A, Ludwig KF, Sorrelle N, Haaland
G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D,
et al: Warfarin blocks gas6-Mediated Axl activation required for
pancreatic cancer epithelial plasticity and metastasis. Cancer Res.
75:3699–3705. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allum WH, Stenning SP, Bancewicz J, Clark
PI and Langley RE: Long-term results of a randomized trial of
surgery with or without preoperative chemotherapy in esophageal
cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elkabets M, Pazarentzos E, Juric D, Sheng
Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, et
al: AXL mediates resistance to PI3Kα inhibition by activating the
EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell
carcinomas. Cancer Cell. 27:533–546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paccez JD, Duncan K, Vava A, Correa RG,
Libermann TA, Parker MI and Zerbini LF: Inactivation of GSK3β and
activation of NF-kB pathway via Axl represents an important
mediator of tumorigenesis in esophageal squamous cell carcinoma.
Mol Biol Cell. 26:821–831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsieh MS, Yang PW, Wong LF and Lee JM: The
AXL receptor tyrosine kinase is associated with adverse prognosis
and distant metastasis in esophageal squamous cell carcinoma.
Oncotarget. 7:36956–36970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sawada G, Niida A, Uchi R, Hirata H,
Shimamura T, Suzuki Y, Shiraishi Y, Chiba K, Imoto S, Takahashi Y,
et al: Genomic landscape of esophageal squamous cell carcinoma in a
japanese population. Gastroenterology. 150:1171–1182. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su H, Hu N, Yang HH, Wang C, Takikita M,
Wang QH, Giffen C, Clifford R, Hewitt SM, Shou JZ, et al: Global
gene expression profiling and validation in esophageal squamous
cell carcinoma and its association with clinical phenotypes. Clin
Cancer Res. 17:2955–2966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Michaylira CZ, Wong GS, Miller CG,
Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim
SB, Herlyn M, et al: Periostin, a cell adhesion molecule,
facilitates invasion in the tumor microenvironment and annotates a
novel tumor-invasive signature in esophageal cancer. Cancer Res.
70:5281–5292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:pp. 15545–15550. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liberzon A, Birger C, Thorvaldsdóttir H,
Ghandi M, Mesirov JP and Tamayo P: The molecular signatures
database (MSigDB) hallmark gene set collection. Cell Syst.
1:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cui Y, Li YY, Li J, Zhang HY, Wang F, Bai
X and Li SS: STAT3 regulates hypoxia-induced epithelial mesenchymal
transition in oesophageal squamous cell cancer. Oncol Rep.
36:108–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Niwa Y, Yamada S, Koike M, Kanda M, Fujii
T, Nakayama G, Sugimoto H, Nomoto S, Fujiwara M and Kodera Y:
Epithelial to mesenchymal transition correlates with tumor budding
and predicts prognosis in esophageal squamous cell carcinoma. J
Surg Oncol. 110:764–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bivona TG and Okimoto RA: AXL receptor
tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer
(Auckl). 6:27–34. 2015.PubMed/NCBI
|
|
33
|
Sato K, Suda K, Shimizu S, Sakai K,
Mizuuchi H, Tomizawa K, Takemoto T, Nishio K and Mitsudomi T:
Clinical, pathological and molecular features of lung
adenocarcinomas with AXL expression. PLoS One. 11:e01541862016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012.PubMed/NCBI
|
